{"id":"bind-014","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BIND-014 uses a proprietary nanoplatform to deliver siRNA that targets the PD-1/PD-L1 pathway, potentially inhibiting the immune checkpoint and enhancing anti-tumor activity. This approach aims to selectively deliver the therapeutic siRNA to tumor cells, reducing off-target effects and improving efficacy.","oneSentence":"BIND-014 is a targeted delivery system for small interfering RNA (siRNA) that targets the PD-1/PD-L1 pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:24:05.621Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT02283320","phase":"PHASE2","title":"A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BIND Therapeutics","startDate":"2014-09","conditions":"KRAS Positive Patients With Non-small Cell Lung Cancer, Squamous Cell Non-small Cell Lung Cancer","enrollment":69},{"nctId":"NCT01812746","phase":"PHASE2","title":"A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"BIND Therapeutics","startDate":"2013-04","conditions":"CRPC, Prostate Cancer","enrollment":42},{"nctId":"NCT01792479","phase":"PHASE2","title":"A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BIND Therapeutics","startDate":"2013-04","conditions":"Non-small Cell Lung Cancer","enrollment":64},{"nctId":"NCT02479178","phase":"PHASE2","title":"A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck","status":"TERMINATED","sponsor":"BIND Therapeutics","startDate":"2015-06","conditions":"Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer","enrollment":73},{"nctId":"NCT01300533","phase":"PHASE1","title":"A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer","status":"COMPLETED","sponsor":"BIND Therapeutics","startDate":"2011-01","conditions":"Metastatic Cancer, Cancer, Solid Tumors","enrollment":58}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BIND-014","genericName":"BIND-014","companyName":"BIND Therapeutics","companyId":"bind-therapeutics","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BIND-014 is a targeted delivery system for small interfering RNA (siRNA) that targets the PD-1/PD-L1 pathway. Used for Metastatic non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}